• Início
  • Resultados da busca
  • Development and in vitro assessment of enzymatically-responsive poly(ethylene glycol) hydrogels for the delivery of therapeutic peptides.

Development and in vitro assessment of enzymatically-responsive poly(ethylene glycol) hydrogels for the delivery of therapeutic peptides.

Biomaterials (2014-09-03)
Amy H Van Hove, Michael-John G Beltejar, Danielle S W Benoit
RESUMO

Despite the recent expansion of peptide drugs, delivery remains a challenge due to poor localization and rapid clearance. Therefore, a hydrogel-based platform technology was developed to control and sustain peptide drug release via matrix metalloproteinase (MMP) activity. Specifically, hydrogels were composed of poly(ethylene glycol) and peptide drugs flanked by MMP substrates and terminal cysteine residues as crosslinkers. First, peptide drug bioactivity was investigated in expected released forms (e.g., with MMP substrate residues) in vitro prior to incorporation into hydrogels. Three peptides (Qk (from Vascular Endothelial Growth Factor), SPARC113, and SPARC118 (from Secreted Protein Acidic and Rich in Cysteine)) retained bioactivity and were used as hydrogel crosslinkers in full MMP degradable forms. Upon treatment with MMP2, hydrogels containing Qk, SPARC113, and SPARC118 degraded in 6.7, 6, and 1 days, and released 5, 8, and, 19% of peptide, respectively. Further investigation revealed peptide drug size controlled hydrogel swelling and degradation rate, while hydrophobicity impacted peptide release. Additionally, Qk, SPARC113, and SPARC118 releasing hydrogels increased endothelial cell tube formation 3.1, 1.7, and 2.8-fold, respectively. While pro-angiogenic peptides were the focus of this study, the design parameters detailed allow for adaptation of hydrogels to control peptide release for a variety of therapeutic applications.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
N,N-Diisopropylethylamine, ReagentPlus®, ≥99%
Sigma-Aldrich
N,N-Diisopropylethylamine, purified by redistillation, 99.5%
Sigma-Aldrich
Piperazine, ReagentPlus®, 99%
Sigma-Aldrich
DIC, 99%
Sigma-Aldrich
Triisopropylsilane, 98%
Sigma-Aldrich
2,2′-(Ethylenedioxy)diethanethiol, 95%
Sigma-Aldrich
HBTU, ≥98.0% (T)
Sigma-Aldrich
Calcein-AM, BioReagent, suitable for fluorescence, ≥95.0% (HPLC)
Sigma-Aldrich
N,N-Diisopropylethylamine, 99.5%, biotech. grade
Sigma-Aldrich
Calcein AM solution, 4 mM in DMSO, ≥90% (HPLC), solution
Sigma-Aldrich
DIC, purum, ≥98.0% (GC)
Sigma-Aldrich
N-Ethyldiisopropylamine, BASF quality, ≥98.0%
Sigma-Aldrich
Thioanisole, ReagentPlus®, ≥99%
Sigma-Aldrich
Calcein-AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
Sigma-Aldrich
Piperazine, BioUltra, anhydrous, ≥99.0% (T)
Amphotericin B, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
MMP-2 human, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
N-Ethyldiisopropylamine solution, suitable for peptide synthesis, ~2 M in 1-methyl-2-pyrrolidinone
Supelco
Piperazine, analytical standard
Sigma-Aldrich
Matrix Metalloproteinase-2 human, >90% (SDS-PAGE), recombinant, expressed in NSO cells, lyophilized powder
Sigma-Aldrich
Diisopropylcarbodiimide solution, 1 M in THF
Sigma-Aldrich
Diisopropylcarbodiimide solution, 1 M in dichloromethane

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.